Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation
Shingo Takahara, Mourad Ferdaoussi, Nikola Srnic, Zaid H. Maayah, Shubham Soni, Anna Katharina Migglautsch, Rolf Breinbauer, Erin E. Kershaw, Jason R.B. Dyck
Abstract
The reduction of lipolysis by adipocyte ATGL inhibition ameliorates cardiac remodeling induced by chronic β-adrenergic stimulation likely via reducing galectin-3 secretion from adipose tissue. Our findings highlight that suppressing lipolysis in adipocytes may be a potential therapeutic target for patients with heart failure whose sympathetic nervous system is activated. Furthermore, galectin-3 might be involved in the mechanisms by which excessive lipolysis in adipose tissues influences remote cardiac pathologies and thus warrants further investigation.
Topics & Concepts
LipolysisAdipose tissueAdipocyteInflammationInternal medicineEndocrinologySecretionMedicineStimulationAdrenergicSympathetic nervous systemHeart failureReceptorBlood pressureGalectins and Cancer BiologySignaling Pathways in DiseaseCardiovascular, Neuropeptides, and Oxidative Stress Research